

# Timothy P Cripe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6508731/publications.pdf>

Version: 2024-02-01

73  
papers

2,274  
citations

172457

29  
h-index

233421

45  
g-index

74  
all docs

74  
docs citations

74  
times ranked

3667  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells. <i>Cancer Research</i> , 2013, 73, 5169-5182.	0.9	155
2	Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. <i>Molecular Therapy</i> , 2015, 23, 602-608.	8.2	132
3	Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3547-3552.	1.6	123
4	Immunotherapy for osteosarcoma: Where do we go from here?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27227.	1.5	117
5	Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3566-3574.	7.0	105
6	Nothing but NET: A review of norepinephrine transporter expression and efficacy of <sup>131</sup> I-β-CIT therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 5-11.	1.5	77
7	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	3.1	76
8	Going back to class I: MHC and immunotherapies for childhood cancer. <i>Pediatric Blood and Cancer</i> , 2015, 62, 571-576.	1.5	68
9	Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1842-1851.	1.6	62
10	Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models. <i>Scientific Reports</i> , 2017, 7, 2396.	3.3	62
11	Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects. <i>Clinical Cancer Research</i> , 2014, 20, 3787-3798.	7.0	61
12	Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 2368-2375.	4.1	60
13	Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1709-1716.	1.5	59
14	Oncolytic virus and PD-1/PD-L1 blockade combination therapy. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 65-77.	6.0	57
15	Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. <i>Cancer Gene Therapy</i> , 2005, 12, 407-416.	4.6	47
16	Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 62-74.	4.4	41
17	First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial. <i>Molecular Therapy</i> , 2019, 27, 1930-1938.	8.2	41
18	Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 82037-82048.	1.8	41

#	ARTICLE	IF	CITATIONS
19	Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. <i>Pediatric Blood and Cancer</i> , 2006, 46, 745-754.	1.5	39
20	Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1555-1565.	4.1	38
21	GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. <i>International Journal of Cancer</i> , 2020, 146, 3184-3195.	5.1	37
22	To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. <i>Viruses</i> , 2016, 8, 43.	3.3	36
23	Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. <i>Pediatric Blood and Cancer</i> , 2005, 44, 469-478.	1.5	35
24	Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?. <i>Biomedicines</i> , 2016, 4, 13.	3.2	35
25	Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 22-30.	4.4	35
26	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. <i>Molecular Therapy</i> , 2013, 21, 1014-1023.	8.2	34
27	Differential Susceptibility of Pediatric Sarcoma Cells to Oncolysis by Conditionally Replication-Competent Herpes Simplex Viruses. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 447-453.	0.6	33
28	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14010.	4.4	33
29	TGF- $\beta$ 2 Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma. <i>Molecular Therapy - Oncolytics</i> , 2017, 7, 17-26.	4.4	33
30	Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2018, 28, 711-716.	0.6	29
31	GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 214-222.	4.4	28
32	Pediatric cancer research: Surviving COVID-19. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28435.	1.5	28
33	Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6479-6494.	7.0	27
34	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. <i>Immunity</i> , 2017, 47, 159-170.e10.	14.3	27
35	Immunotherapeutic Challenges for Pediatric Cancers. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 38-48.	4.4	26
36	A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 884.	4.8	26

#	ARTICLE	IF	CITATIONS
37	Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. <i>Oncotarget</i> , 2017, 8, 17412-17427.	1.8	24
38	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. <i>Cancer Research</i> , 2017, 77, 5706-5711.	0.9	22
39	High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. <i>Viruses</i> , 2018, 10, 132.	3.3	22
40	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	5.9	20
41	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15015.	4.4	19
42	Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. <i>Lancet Respiratory Medicine</i> , 2022, 10, 403-420.	10.7	19
43	Effect of Combined Cyclooxygenase-2 and Matrix Metalloproteinase Inhibition on Human Sarcoma Xenografts. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 709-714.	0.6	17
44	Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects. <i>Molecular Cancer Research</i> , 2020, 18, 1074-1087.	3.4	15
45	Ewing Sarcoma Family of Tumors Express Adenovirus Receptors and Are Susceptible to Adenovirus-Mediated Oncolysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 527-533.	0.6	12
46	Characterization of MHC Class I and Î²2-microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 618-626.	1.5	12
47	Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. <i>Oncotarget</i> , 2018, 9, 21348-21358.	1.8	12
48	Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1550-1554.	1.5	11
49	Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15016.	4.4	11
50	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27313.	1.5	11
51	Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNÎ²-NIS (VV1) oncolytic virus in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3090-3090.	1.6	10
52	EXPLOITING GENETIC ALTERATIONS TO DESIGN NOVEL THERAPIES FOR CANCER. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 657-675.	2.2	8
53	A multiyear quality improvement project to increase influenza vaccination in a pediatric oncology population undergoing active therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27268.	1.5	8
54	Emerging cancer-targeted therapies. <i>Pediatric Clinics of North America</i> , 2002, 49, 1339-1368.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. <i>Science Advances</i> , 2022, 8, .	10.3	7
56	Therapeutic modulation of the CD47-SIRP $\alpha$ axis in the pediatric tumor microenvironment: working up an appetite. , 2020, 3, 550-562.		6
57	Please stand by: how oncolytic viruses impact bystander cells. <i>Future Virology</i> , 2018, 13, 671-680.	1.8	5
58	Immunotherapies for Pediatric Solid Tumors: A Targeted Update. <i>Paediatric Drugs</i> , 2022, 24, 1-12.	3.1	5
59	Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. <i>Pharmaceutical Research</i> , 2016, 33, 2722-2735.	3.5	3
60	Evidence for Oncolytic Viral Eradication of Cholesteatoma In Vitro. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 891-893.	1.9	3
61	Gene Editing Thumbs a Ride with Oncolytic Virotherapy. <i>Molecular Therapy</i> , 2020, 28, 2103-2104.	8.2	3
62	Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1258, 77-89.	1.6	3
63	The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy. <i>Pediatric Pulmonology</i> , 2021, 56, 729-737.	2.0	2
64	A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2541-2541.	1.6	2
65	Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma. <i>IScience</i> , 2021, 24, 102759.	4.1	1
66	Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. , 2021, 9, e002939.		1
67	A phase I dose-escalation study of intratumoral herpes simplex virus-1 mutant HSV1716 in pediatric/young adult patients with refractory non-central nervous system solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10047-10047.	1.6	1
68	A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy. <i>Current Drug Delivery</i> , 2019, 16, 807-817.	1.6	1
69	Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors. <i>British Journal of Radiology</i> , 2022, 95, 20211088.	2.2	1
70	ET-27 * REPLICATION AND SPREAD OF ONCOLYTIC HERPES VIRUS IN GLIOMA STEM CELLS CAN BE ENHANCED BY SPECIFIC INHIBITION OF HISTONE DEACETYLASE 6. <i>Neuro-Oncology</i> , 2014, 16, v85-v85.	1.2	0
71	Pediatric Oral/Maxillofacial Soft Tissue Sarcomas: A Clinicopathologic Report of Four Cases. <i>Case Reports in Oncology</i> , 2016, 9, 447-453.	0.7	0
72	After Hollywood Opened the Door, What Do We See in the Halls of Academic Medicine?. <i>Academic Medicine</i> , 2018, 93, 1099-1100.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 281-285.	1.8	0